Kevin Rosenblatt, Mary Lake Polan, Daniel Chan, Thomas McElrath
NX Prenatal has appointed Kevin Rosenblatt, Mary Lake Polan, Daniel Chan, and Thomas McElrath to its newly formed medical/clinical advisory board. Rosenblatt will serve as the chair and currently works as chief medical and scientific officer for the company. Prior to NX Prenatal, he served as chief medical officer/chief scientific officer of CompanionDx Labs. Polan is a clinical professor in the department of obstetrics and gynecology and reproductive science at Yale University School of Medicine. She also serves as chair emeritus of the department of obstetrics and gynecology at Stanford University. Chan is a professor of pathology, oncology, radiology, and urology at Johns Hopkins University School of Medicine. He also serves as director of the clinical chemistry division and co-director of the Pathology Core Laboratory of Johns Hopkins Hospital in Baltimore. McElrath is an associate professor of obstetrics, gynecology, and reproductive biology at Harvard Medical School. He is also an attending physician at Brigham and Women's Hospital.
Mary Duseau, Paul Thomas
Roka Biosciences, a manufacturer of molecular diagnostics for foodborne pathogens, has named Mary Duseau as president and CEO. She succeeds Paul Thomas, who held those posts since 2009 and will now serve as chairman of the firm's board of directors. Duseau has been senior vice president and chief commercial officer at Roka since 2015. She was previously global sales director at Andor Technologies, a division of Oxford Instruments, and held various sales and management positions at PerkinElmer between 2000 and 2012.
James Lewis
James Lewis has joined cancer genome testing firm Personal Genome Diagnostics as senior vice president of corporate development. He will oversee strategic planning, collaboration initiatives, and fundraising activities directed at securing capital to meet corporate objectives, including a planned Series B financing round this year. Lewis was previously VP of business development at Esperance Pharmaceuticals. Before that, he was at AstraZeneca, where he led business development work for the cardiovascular franchise and was on the Crestor commercial team.
For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.